Arcutis Biotherapeutics Inc

+1.00 (+4.81%)
Products, Regulatory

Arcutis Provides Update On Phase 2A Clinical Trial Evaluating Arq-252 Cream As A Potential Treatment For Vitiligo

Published: 07/01/2021 10:17 GMT
Arcutis Biotherapeutics Inc (ARQT) - Arcutis Provides Update on Phase 2a Clinical Trial Evaluating Arq-252 Cream As a Potential Treatment for Vitiligo.
Arcutis Biotherapeutics Inc - Announced Its Decision to Terminate Recently Initiated Phase 2a Clinical Trial Evaluating Arq-252.
Arcutis Biotherapeutics - Formulation-related Observations From Arq-252 Trial in Chronic Hand Eczema Informed Early Termination of Phase 2a Arq-252 Trial.
Arcutis Biotherapeutics Inc - Progressing New Formulation With Goal of Greater Drug Delivery to Targets in Skin.
Arcutis Biotherapeutics Inc - Vitiligo Study is Not Being Terminated for Any Safety Or Tolerability Reasons.